America's biopharmaceutical companies are using biological processes to
develop 907 medicines and vaccines targeting more than 100 diseases, according
to a new report (PDF) released today by the Pharmaceutical Research
and Manufacturers of America (PhRMA).
The report includes biologics in human clinical trials or under review by FDA
such as 338 cancer therapeutics that target several different types of solid
tumors, leukemia and lymphoma; 134 vaccines for infectious diseases; 71
medicines for autoimmune diseases including lupus, multiple sclerosis, and
rheumatoid arthritis; and 58 treatments for cardiovascular disease.
Among the biologic medicines in development are a genetically-modified
virus-based vaccine to treat melanoma; a monoclonal antibody for the treatment
of asthma; an antisense therapy for the treatment of leukemia; a recombinant
fusion protein to treat Type II diabetes.
No comments:
Post a Comment